Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 3/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111190 | 0.93 | TLR4 (0.37) | RORCP2RX7KCNA5KMT2A | |
| SCHEMBL19970506 | 0.85 | P2RX7 (0.36) | RORCP2RX7KCNA5TGM2CYP1A2 | |
| SCHEMBL19970509 | 0.83 | ALDH1A1 (0.35) | P2RX7ALDH1A1GAAKMT2ACYP1A2 | |
| SCHEMBL20111187 | 0.81 | TLR4 (0.39) | RORCALDH1A1GAACYP1A2 | |
| SCHEMBL19970520 | 0.77 | ALDH1A1 (0.32) | ALDH1A1GAA | |
| SCHEMBL19970497 | 0.75 | ALDH1A1 (0.37) | P2RX7ALDH1A1GAAKMT2ACYP1A2 | |
| SCHEMBL19970495 | 0.74 | CYP2D6 (0.34) | P2RX7ALDH1A1GAAKMT2AHTR2A | |
| SCHEMBL19970490 | 0.73 | ALDH1A1 (0.32) | ALDH1A1GAAKMT2A | |
| SCHEMBL19970529 | 0.72 | MAPT (0.34) | RORCP2RX7ALDH1A1GAAKMT2A | |
| SCHEMBL4153914 | 0.72 | TLR4 (0.48) | KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | RORC 1169/4885P2RX7 57/4885KCNA5 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.